Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice.

•Agonists for FXR (e.g., OCA) and GLP-1R are leading clinical candidates for NASH.•First preclinical evidence for OCA alone or added to GLP-1R agonist IP118 on NASH and metabolism.•OCA + IP118 exerted greater reductions in key morphologic features of NASH.•OCA + IP118 synergistically reduced body weight in DIO mice.•FXR and GLP-1 co-activation may be therapeutically beneficial.